177 related articles for article (PubMed ID: 33184634)
1. Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
Pham HT; Alves BM; Yoo S; Xiao MA; Leng J; Quashie PK; Soares EA; Routy JP; Soares MA; Mesplède T
J Antimicrob Chemother; 2021 Feb; 76(3):639-647. PubMed ID: 33184634
[TBL] [Abstract][Full Text] [Related]
2. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
3. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
5. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
[TBL] [Abstract][Full Text] [Related]
6. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
7. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
Pham HT; Mesplède T; Wainberg MA
Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
[TBL] [Abstract][Full Text] [Related]
9. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
[TBL] [Abstract][Full Text] [Related]
10. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
[TBL] [Abstract][Full Text] [Related]
11. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
14. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
15. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
[TBL] [Abstract][Full Text] [Related]
16. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.
Mesplède T; Quashie PK; Hassounah S; Osman N; Han Y; Liang J; Singhroy DN; Wainberg MA
AIDS; 2015 Jul; 29(12):1459-66. PubMed ID: 26244385
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.
Anstett K; Cutillas V; Fusco R; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2016 Aug; 71(8):2083-8. PubMed ID: 27084918
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
19. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
20. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.
Wares M; Mesplède T; Quashie PK; Osman N; Han Y; Wainberg MA
Retrovirology; 2014 Jan; 11():7. PubMed ID: 24433497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
